LUS to Assess Lung Injury After Lung Resection (THORUS)

Ultrasound Assessment of Aeration Changes After Lung Resection: a Pilot Study

The purpose of the study is to assess whether lung ultrasound is able to detect lung injury after lung resection surgery.

Study Overview

• Status: Recruiting
• Conditions: Postoperative Complications; Lung Cancer; Lung Injury; Lung Injury, Ventilator Induced; Lung Neoplasm; Thoracic; Adult ALL; Lung Inflammation; Lung Ischemia/Hypoxia; Postoperative Respiratory Complication

Detailed Description

Postoperative pulmonary complications (PPC) are common after lung resection surgery, with an incidence that ranges between 11-32%. As PPC are associated with worse outcomes, many studies aim to find predictors that identify high risk patients and prompt specific interventions and/or monitoring and hence, improve outcomes. PPC result from lung injury inherent to lung resection surgery. Lung aeration changes seen with lung ultrasound (LUS) could detect lung injury and thus, identify patients at high risk of PPC. The underlying mechanisms of lung injury are different in the dependent and non-dependent lung; oxidative stress in both lungs, lung injury associated with one-lung ventilation in the dependent lung and ischemia/reperfusion or surgical manipulation in the non-dependent lung. LUS evaluates the operated and non-operated lung separately and so it can be valuable in understanding the characteristics and intensity of lung injury in each lung specifically.

This is a prospective, single-centre, observational study in which 28 consecutive participants with non-small cell lung cancer scheduled for lobectomy will be recruited. Participants will be divided in two groups depending on the surgical approach. First group will be lobectomy via thoracotomy. Second group will be lobectomy via VATS. Participants will be recruited consecutively until there are 14 patients in each group. LUS will be performed in each participant's dependent and non-dependent lung at three predefined time points: before surgery, after extubation and 24 h after surgery. Each hemithorax will be divided into 6 areas: anterior, lateral and posterior, separated by the anterior and posterior axillary lines, each divided into upper and lower zones. For each echographic examination, cineloops of the most pathological findings in each area will be stored and analysed offline by two independent and blinded anesthesiologists. From these, a semiquantitative score, the modified lung ultrasound score (mLUSS), will be calculated for each hemithorax to assess lung aeration at each time point. The level of agreement for mLUSS will be tested. At the same predefined time points blood plasma samples will be collected, flash-frozen and stored in order to measure levels of the inflammatory mediators IL-6, IL-10 and TNFα.

The invertigators hypothesise that LUS can detect lung injury after lung resection surgery. The primary objective of the study is to assess changes in lung aeration after lung resection with mLUSS. Secondary objectives are, first, to describe LUS findings after lung resection surgery, second, to assess the ability of mLUSS to detect oxygenation changes after lung resection and third, to compare the behaviour of inflammatory mediators in plasma with mLUSS changes.

• Study Type: Observational
• Enrollment (Anticipated): 28

Contacts and Locations

• Study Contact: Name: Ana Broseta Lleó, Consultant; Phone Number: 187554 0034963187554; Email: ana.broseta@gmail.com

Study Locations

• Spain
  • Valencia, Spain, 46014
    • Recruiting
    • Hospital General Universitario de Valencia
    • Contact: Ana Broseta Lleó, Consultant; Email: ana.broseta@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

patients assigned to a tertiary referral hospital

Description

Inclusion Criteria:

• Age > 18
• ASA I-III
• Non-small cell lung neoplasm
• Elective lung resection
• Via VATS
• Under one-lung ventilation

Exclusion Criteria:

• pregnancy
• Diagnosed pulmonary fibrosis
• Scheduled surgery limited to biopsy
• Surgery that includes resection of the thoracic wall or the diaphragm
• Predicted FEV1 < 40%
• Neoplasm metastasis
• Obesity class II or more (BMI ≥ 35 kg/m^2)
• Risk of malnutrition CONUT > 1
• Hemoglobin < 10 g/dl
• Chronic kidney failure: glomerular filtration < 60 ml/min/m^2, nephrectomy, kidney transplantation
• Treatment with corticosteroids or immunosuppressive agents 3 months before surgery
• Transfusion of blood products during the previous 10 days
• Heart failure (New York Heart Association Functional Class 3 or 4) during the week before surgery.
• Heart valve diseases over stage B of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2014
• Diastolic dysfunction

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Lung resection less than lobectomy; participants scheduled for lung resection that is less than lobectomy
Lung resection equal to or greater than lobectomy; participants scheduled for lung resection that is equal to or greater than lobectomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in mLUSS after lung resection	The modified lung ultrasound score (mLUSS) ranges 0-36; the higher the score, the less aeration (worse).	preoperative vs immediate postoperative period vs 24 hours after surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
LUS findings in the dependent and non-dependent lung	description of LUS findings after lung resection surgery in each lung	preoperative vs immediate postoperative period vs 24 hours after surgery
Changes in oxygenation (PAFI) after lung resection	PAFI is the ratio between paO2 and fraction of inspired oxygen; the lower, the worse.	preoperative vs immediate postoperative vs 24 hours after surgery
Changes in plasma cytokine IL-6 after lung resection		preoperative vs immediate postoperative vs 24 hours after surgery
Changes in plasma cytokine IL-10 after lung resection		preoperative vs immediate postoperative vs 24 hours after surgery
Changes in plasma TNFα after lung resection		preoperative vs immediate postoperative vs 24 hours after surgery
Changes in blood bone natriuretic peptide (BNP) after lung resection.		preoperative vs immediate postoperative vs 24 hours after surgery

Collaborators and Investigators

• Sponsor: Ana Broseta Lleó
• Collaborators: Hospital General Universitario de Valencia
• Investigators: Principal Investigator: Ana Broseta Lleó, Consultant, Hospital General Universitario de Valencia

Study record dates

Study Major Dates

• Study Start (Actual): December 20, 2020
• Primary Completion (Anticipated): December 30, 2022
• Study Completion (Anticipated): April 1, 2023

Study Registration Dates

• First Submitted: November 24, 2020
• First Submitted That Met QC Criteria: December 15, 2020
• First Posted (Actual): December 21, 2020

Study Record Updates

• Last Update Posted (Actual): November 1, 2022
• Last Update Submitted That Met QC Criteria: October 30, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: lung injury; lung ultrasound; thoracic surgery; postoperative complications; cytokines blood
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Signs and Symptoms, Respiratory; Thoracic Injuries; Lung Neoplasms; Ischemia; Inflammation; Pneumonia; Wounds and Injuries; Postoperative Complications; Hypoxia; Lung Injury; Ventilator-Induced Lung Injury
• Other Study ID Numbers: THORUS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No